Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corp (BCPC) delivers specialty performance ingredients for nutrition and industrial markets through advanced technologies. This news hub provides investors and industry professionals with essential updates on corporate developments and market leadership.
Access authoritative reporting on earnings announcements, product innovations, and strategic partnerships. Our curated collection ensures you stay informed about BCPC's advancements in microencapsulation techniques and chelation technology across human/animal nutrition sectors.
Discover press releases detailing regulatory milestones, manufacturing expansions, and sustainability initiatives. All content is verified for accuracy, offering neutral analysis without speculative commentary.
Bookmark this page for real-time access to Balchem's financial disclosures and operational updates. Regularly refreshed content supports informed decision-making for stakeholders tracking specialty chemical markets.
Balchem (NASDAQ: BCPC) will present at Baird’s 55th Annual Global Industrial Conference on November 12, 2025. Key speakers scheduled are Ted Harris (Chairman, President & CEO), Martin Bengtsson (CFO) and Allison Baurichter (Senior Director Investor Relations).
The presentation signals management engagement with investors at a major industry conference; no financial data, times, or webcast details were provided.
Balchem (NASDAQ: BCPC) reported third quarter fiscal 2025 results for the period ended September 30, 2025: net sales $267.6M (up 11.5% vs. prior year), net earnings $40.3M (up 19.1%), adjusted EBITDA $71.4M (up 11.0%), and free cash flow $50.7M. Cash from operations was $65.6M. Net debt was reduced to $88.9M with a leverage ratio of 0.3x. The Human Nutrition and Health segment reported record sales of $174.1M (up 14.3%).
Recent milestones include approvals to build a new microencapsulation facility in Orange County, NY, and five new sponsored research studies published in the quarter, including a choline biomarker study.
Balchem (NASDAQ: BCPC) will hold a conference call on Tuesday, October 21, 2025 at 11:00 AM ET to review third quarter 2025 results. The company said results and accompanying financial exhibits will be released prior to the market open on October 21, 2025.
Management presenters are Ted Harris, Chairman, President and CEO, and Martin Bengtsson, CFO. Institutional investors and analysts can join by dial-in numbers provided, and the public may listen via a live webcast at https://events.q4inc.com/attendee/857727932. A replay will be available at the same link for one year after the call.
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focused on health and nutrition markets, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 9, 2025.
The company will be represented by key executives including Ted Harris (Chairman, President and CEO), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director of Investor Relations).
Balchem Corporation (NASDAQ: BCPC) reported strong Q2 2025 financial results with record net sales of $255.5 million, up 9.1% year-over-year. The company achieved net earnings of $38.3 million, a 19.4% increase, and record adjusted EBITDA of $69.2 million, up 11.2%.
All three business segments showed growth, with Human Nutrition and Health achieving record sales of $160.8 million (up 8.7%), Animal Nutrition and Health reaching $56.0 million (up 13.1%), and Specialty Products posting record sales of $37.2 million (up 6.0%).
Key developments include plans for a new $36 million micro-encapsulation facility in Orange County, NY, and the European Commission's implementation of 95.4% to 120.8% anti-dumping duties on Chinese choline chloride imports.
Balchem Corporation (NASDAQ: BCPC) has scheduled its second quarter 2025 financial results conference call for July 31, 2025, at 11:00 AM Eastern Time. The company's Chairman, President and CEO Ted Harris, along with CFO Martin Bengtsson, will host the call.
The Q2 2025 results will be released before market opening on the same day and will be available on www.balchem.com. Institutional investors and analysts can join by dialing 800-715-9871 (USA/Canada toll-free). A live webcast and replay will be accessible at the company's investor events portal.
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focused on health and nutrition markets, has announced its participation in the upcoming CJS Annual New Ideas Summer Conference on July 10, 2025. The company will be represented by key executives including Ted Harris (Chairman, CEO, and President), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director Investor Relations).
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focused on health and nutrition markets, has announced its participation in the upcoming Wells Fargo Industrials and Materials Conference scheduled for June 11, 2025. The company will be represented by key executives including Ted Harris (Chairman of the Board, CEO, and President), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director Investor Relations) who will present at the conference.
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focusing on health and nutrition markets, has announced its participation in the upcoming dbAccess Global Consumer Conference scheduled for June 4, 2025. The company will be represented by Ted Harris, who serves as Chairman of the Board, Chief Executive Officer, and President, along with Martin Bengtsson, the Chief Financial Officer.
Balchem (NASDAQ: BCPC) reported strong Q1 2025 financial results with record net sales of $250.5 million, up 4.5% year-over-year. The company achieved net earnings of $37.1 million, a 27.8% increase, and record adjusted EBITDA of $66.3 million, up 8.9% from the prior year quarter.
All three segments - Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products - showed sales and earnings growth. The Human Nutrition segment led with record sales of $158.5 million, while gross margin improved to 35.2%, up 120 basis points. Operating expenses decreased to $37.2 million, and free cash flow was $31.0 million.
The company maintains a strong financial position with $49.9 million in cash and continues to invest in growth initiatives despite global trade uncertainties.
FAQ
What is the current stock price of Balchem (BCPC)?
What is the market cap of Balchem (BCPC)?
